Mark Bachleda - 09 Jun 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Charles Newton as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
09 Jun 2025
Net transactions value
$0
Form type
4
Filing time
11 Jun 2025, 17:48:27 UTC
Previous filing
20 Mar 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bachleda Mark Director C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO /s/ Charles Newton as Attorney-in-Fact 11 Jun 2025 0001887762

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +13,000 $0.000000 13,000 09 Jun 2025 Common Stock 13,000 $12.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares of Common Stock subject to the option shall vest on a monthly basis following the grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the Reporting Person remaining in service as a director through the applicable vesting date.